Vercise Genus News Today

Boston Scientific recently issued an urgent field safety notice for certain Vercise Genus DBS implantable pulse generators.

Medtronic plc received the greenlight from the U.S. FDA for its latest deep brain stimulation system, the Percept RC. The rechargeable neurostimulator includes the company’s sensing technology which captures data from brain signals and allows for more personalized therapy.

Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming. DUBLIN, Jan. 8, 2024...

/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its...

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.

While devices that stimulate the brain invasively have generally been available since 2002, and devices that do so non-invasively have been available since 2013, in recent years, the...

MARLBOROUGH, Mass., July 27, 2023 /PRNewswire/ -- Boston Scientific Corporation generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis,...

MARLBOROUGH, Mass., Jul. 11, 2023 -- Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration approval for the Vercise™ Neural Navigator 5...

Boston Scientific (NYSE:BSX) announced today that the FDA approved its Vercise Neural Navigator 5 software.

Boston Scientific Wins Two Edison Awards